If you have been reading about visceral fat and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-25. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
==== List of regions ==== Sometimes, overlaps and transition areas happen between the various regions of Lower Saxony. Several of the regions listed here are part of other, larger regions, that are also included in the list.
==== Action and reference level ==== WHO presented in 2009 a recommended reference level (the national reference level), 100 Bq/m3, for radon in dwellings. The recommendation also says that where this is not possible, 300 Bq/m3 should be selected as the highest level. A national reference level should not be a limit, but should represent the maximum acceptable annual average radon concentration in a dwelling. The actionable concentration of radon in a home varies depending on the organization doing the recommendation, for example, the EPA encourages that action be taken at concentrations as low as 74 Bq/m3 (2 pCi/L), and the European Union recommends action be taken when concentrations reach 400 Bq/m3 (11 pCi/L) for old houses and 200 Bq/m3 (5 pCi/L) for new ones. On 8 July 2010, the UK's Health Protection Agency issued new advice setting a "Target Level" of 100 Bq/m3 whilst retaining an "Action Level" of 200 Bq/m3. Similar levels (as in the UK) are published by Norwegian Radiation and Nuclear Safety Authority (DSA) with the maximum limit for schools, kindergartens, and new dwellings set at 200 Bq/m3, where 100 Bq/m3 is set as the action level.
=== Batch reactor === Batch reactors are reactors in which the reactants are put in the reactor at time 0 and react until the reaction is stopped. Consequently, the space time is the same as the average residence time in a batch reactor.
Sources: en.wikipedia.org
==== Distribution ==== The volume of distribution of ramelteon is 73.6 L, which suggests substantial tissue distribution. The plasma protein binding of ramelteon is 82% independently of concentration. Ramelteon is primarily bound to albumin (70%). The medication is not selectively distributed to red blood cells.
== Usage == Deltamethrin is a highly effective insecticide. It is used, among other applications, for the production of long-lasting insecticidal nets (LLINs), which, along with indoor residual spraying (IRS), are the main vector control strategies recommended by the World Health Organization (WHO) for the management of malaria. Deltamethrin plays a key role in controlling malaria vectors, and is used in the manufacture of long-lasting insecticidal mosquito nets. It is used as one of a battery of pyrethroid insecticides in control of malarial vectors, particularly Anopheles gambiae, and whilst being the most employed pyrethroid insecticide, can be used in conjunction with, or as an alternative to, permethrin, cypermethrin and organophosphate-based insecticides, such as malathion and fenthion. Resistance to deltamethrin (and its counterparts) is now extremely widespread and threatens the success of worldwide vector control programmes.
Several medications are effective in treating scabies, and on a population-wide basis also reduce hospital and primary care presentations for secondary bacterial infections which can follows scabies. Treatment should involve the entire household and any others who have had recent, prolonged contact with the infested individual. In addition to treating the infestation, options to control itchiness include antihistamines and prescription anti-inflammatory agents. Bedding, clothing and towels used during the previous three days should be washed in hot water and dried in a hot dryer. Treatment protocols for crusted scabies are significantly more intense than for common scabies.
Sources: en.wikipedia.org
==== Na+,K+-ATPase and Insect resistance to cardiotonic steroids ==== Many examples of convergent evolution exist in insects in terms of developing resistance at a molecular level to toxins. One well-characterized example is the evolution of resistance to cardiotonic steroids (CTSs) via amino acid substitutions at well-defined positions of the α-subunit of Na+,K+-ATPase (ATPalpha). Variation in ATPalpha has been surveyed in various CTS-adapted species spanning six insect orders. Among 21 CTS-adapted species, 58 (76%) of 76 amino acid substitutions at sites implicated in CTS resistance occur in parallel in at least two lineages. 30 of these substitutions (40%) occur at just two sites in the protein (positions 111 and 122). CTS-adapted species have also recurrently evolved neo-functionalized duplications of ATPalpha, with convergent tissue-specific expression patterns.
HbO2 + CO ⇌ Hb(CO) + O2 is established in the blood of cigarette smokers. Chelation therapy is based on the principle of using chelating ligands with a high binding selectivity for a particular metal to remove that metal from the human body. Complexes with polyamino carboxylic acids find a wide range of applications. EDTA in particular is used extensively.
== Controversy == In 2024, an Oregon man and the ACLU of Oregon filed a lawsuit against Grifols for its alleged "forever ban" on accepting plasma from gay men. The ACLU of Oregon states this alleged ban is discriminatory and a violation of Oregon's public accommodations laws. The plaintiff sought nearly $1 million in damages. In 2025, the U.S. Equal Employment Opportunity Commission (EEOC) sued Grifols for failing to accommodate a job applicant's disability, a violation of the Americans with Disabilities Act. In 2025, a Manitoba man sued Grifols, claiming a machine malfunction during plasmapheresis caused him a serious kidney injury. After the deaths of two individuals who gave plasma at Grifols facilities in Winnipeg, the company halted plasma collection in Canada effective August 2026 but indicated it remains ready to resume.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.